Actively Recruiting

Age: 0Years - 18Years
All Genders
NCT06904027

A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders

Led by Tongji Hospital · Updated on 2026-04-27

40

Participants Needed

5

Research Sites

290 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Urea cycle disorders (UCD) are rare diseases in China, would lead to high mortality and disability, which require long-term management due to the recurrent symptoms. This multi-center, prospective, single-arm study was designed to assess the efficacy and safety of Glycerol Phenylbutyrate for Chinese pediatric patients with UCD, to provide the additional references and treatment options for Chinese UCD patients, and enhance the clinical management of UCD in China. This study primarily observes patients with UCD who are on long-term treatment with glyceryl phenylbutyrate, the total planned observation period is 5 years.

CONDITIONS

Official Title

A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders

Who Can Participate

Age: 0Years - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged 0-18 years
  • Willingness to follow the treatment, dietary management, and visit schedule, and signing informed consent
  • Diagnosis with one of the following UCD subtypes: carbamoyl phosphate synthetase I deficiency, ornithine translocase deficiency, citrullinemia type I, argininosuccinic aciduria, argininemia, or HHH syndrome
  • Planned use of glycerol phenylbutyrate with no use in the past 3 months (including the past 3 months)
  • For men with fertility and women of childbearing potential: willingness to use effective contraception from consent signing to 1 month after last dose, and negative pregnancy test within 7 days before starting study drug
Not Eligible

You will not qualify if you...

  • Allergy to phenylbutyrate, phenylacetate acid, phenylacetyl glutamine, or excipients
  • Use of drugs affecting renal clearance, protein catabolism, or increasing blood ammonia within 24 hours before first dose
  • Use of other nitrogen-scavenging agents after enrollment
  • Pregnant or breastfeeding females
  • Any other condition judged by the investigator to affect compliance or safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Peking University First Hospital

Beijing, Beijing Municipality, China, 100034

Actively Recruiting

2

Guangzhou Women and Children's Medical Center

Guangzhou, Guangdong, China, 510000

Actively Recruiting

3

Tongji Hosipital

Wuhan, Hubei, China, 430030

Actively Recruiting

4

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China, 200092

Actively Recruiting

5

Children's Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Actively Recruiting

Loading map...

Research Team

X

Xiaoping Luo, M.D.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here